Phase 2 study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis Meeting Abstract

  

Authors:	Lee, C. H.; Shah, A. Y.; Makker, V.; Taylor, M.; Shaffer, D.; Hseih, J. J.; Cohn, A. L.; Di Simone, C.; Marin, A. P.; Rasco, D.; Gunnestad-Ribe, S.; Richards, D. A.; Stepan, D. E.; Dutcus, C. E.; Wu, J.; Schmidt, E. V.; Perini, R.; Young, L.; Motzer, R.
Abstract Title:	Phase 2 study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis
Meeting Title:	46th Annual Scientific Meeting of the Clinical Oncology Society of Australia (COSA)
Journal Title:	Asia-Pacific Journal of Clinical Oncology
Volume:	15
Issue:	Suppl. 9
Meeting Dates:	2019 Nov 12-14
Meeting Location:	Adelaide, Australia
ISSN:	1743-7555
Publisher:	Wiley Blackwell
Date Published:	2019-11-01
Start Page:	101
End Page:	102
Language:	English
ACCESSION:	WOS:000493438400124
PROVIDER:	wos
PUBMED:	31674106
DOI:	10.1111/ajco.13262
Notes:	Meeting Abstract: 127 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/157353